BrainStorm

News

News

Press Releases

Date Title and Summary Additional Formats
Toggle Summary BrainStorm Issues 2018 Letter to Shareholders
NEW YORK , Dec. 27, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders. Dear Valued Shareholder, This past year was an extraordinary success for
View HTML
Toggle Summary BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial
BrainStorm has contracted with the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute, currently supporting the Phase 3 ALS Trial, to Produce NurOwn® NEW YORK and BOSTON , Dec. 26, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI),
View HTML
Toggle Summary FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis
U.S. Phase 2 Study to Begin in First Quarter of 2019     NEW YORK , Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that the
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND
Poster highlights enrichment strategies for clinical trials in ALS NEW YORK , Dec. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis
NEW YORK , Nov. 19, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that it has submitted an Investigational New Drug (IND) application
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences
Highlights Preclinical Research and Continued Progress of NurOwn® Platform in ALS Pivotal Trial NEW YORK and PETACH TIKVAH, Israel , Nov. 07, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for
View HTML
Toggle Summary BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update
Highlights Scientific Advances and Continued Progress for NurOwn ® in ALS Towards U.S. FDA Approval; Following Successful FDA Pre-IND Meeting, BrainStorm will File an IND for NurOwn ® in a Second Clinical Indication Conference Call and Webcast Today at 8:30am Eastern Time NEW YORK , Oct.
View HTML
Toggle Summary BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29
Conference Call and Live Webcast at 8:30am Eastern Time NEW YORK and PETACH TIKVAH, Israel , Oct. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for
View HTML
Toggle Summary BrainStorm Poster Receives Clinical Abstract Award at NEALS Conference
Translational Insights Support NurOwn ® as a Best-In-Class Strategy in ALS NEW YORK and PETACH TIKVAH, Israel , Oct. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating
View HTML
Toggle Summary BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALS
NurOwn® to be Featured at NEALS and Cell & Gene Meeting on the Mesa Conferences NEW YORK and PETACH TIKVAH, Israel , Oct. 03, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative adult stem cell therapeutics for debilitating neurodegenerative
View HTML
Toggle Summary BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn®
NEW YORK and PETACH TIKVAH, Israel , Sept. 13, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the United States Patent Office (USPTO) has granted a new US patent
View HTML
Toggle Summary BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform
NEW YORK and PETACH TIKVAH, Israel , Sept. 12, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that members of BrainStorm’s executive team will present and
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference
Presentation and Live Webcast on Thursday, September 6th, 2.10pm ET NEW YORK and PETACH TIKVAH, Israel , Sept. 05, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the
View HTML
Toggle Summary BrainStorm Appoints Arturo Araya as Chief Commercial Officer
Mr. Araya was Global Head of Commercial of Novartis Cell & Gene Therapies Unit Appointment strengthens leadership team with nearly 20 years of global pharmaceutical marketing and commercialization experience NEW YORK and PETACH TIKVAH, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference
NEW YORK and PETACH TIKVAH, Israel , Aug. 29, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the H.C.
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn® Therapy for ALS
NEW YORK , and PETACH TIKVA, Israel , Aug. 23, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has completed the
View HTML
Toggle Summary BrainStorm Announces Grant of a New European Patent for NurOwn®
NEW YORK and PETACH TIKVAH, Israel, July  25, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has granted an European-wide patent
View HTML
Toggle Summary BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update
Conference Call and Webcast at 8.30am ET Today NEW YORK and PETACH TIKVAH, Israel , July 23, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the second
View HTML
Toggle Summary BrainStorm to Announce Second Quarter Financial Results of 2018 and Provide a Corporate Update on Monday July 23
Conference Call and Live Webcast at 8.30am ET NEW YORK and PETACH TIKVAH, Israel , July 17, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the second
View HTML
Toggle Summary BrainStorm Granted Japanese Patent for NurOwn®
NEW YORK and PETACH TIKVAH, Israel, July 5, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has received a Decision to Grant notice from the Japanese Patent Office
View HTML
Toggle Summary BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® Production
NEW YORK , PETACH TIKVA, Israel and BOSTON , July 2, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has contracted with the Connell and O'Reilly Families Cell
View HTML
Toggle Summary BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
Susan Ward, Ph.D. (Pfizer) Appointed Head of Clinical Operations Joe Petroziello (Juno Therapeutics) Appointed VP of Scientific & Corporate Communications NEW YORK and PETACH TIKVAH, Israel, June 28, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm Provides Update on "Right to Try" Policy
  Webcast and Conference Call at 8:30am Eastern Time Today NEW YORK and PETACH TIKVA, Israel , June 26, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that after careful
View HTML
Toggle Summary BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" Policy
Conference Call and Live Webcast at 8:30am Eastern Time NEW YORK and PETACH TIKVAH, Israel , June 25, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call tomorrow,
View HTML
Toggle Summary BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share
NEW YORK and PETACH TIKVA, Israel , June 7, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise Agreement with certain holders of warrants
View HTML
Toggle Summary BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing
Conference call and live webcast on June 7th at 8:15am EDT NEW YORK and PETACH TIKVAH, Israel, June 1, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that the company will
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention
NEW YORK and PETACH TIKVAH, Israel , May 30, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the BIO International
View HTML
Toggle Summary BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation
NEW YORK and PETACH TIKVAH, Israel , May 25, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issues a statement following Congress passing the Federal "Right-to-Try" bill.
View HTML
Toggle Summary BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights
Call Today and Webcast @ 8:30am Eastern Time Today NEW YORK, N.Y. and PETACH TIKVAH, Israel , May 14, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the
View HTML
Toggle Summary BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and PETACH TIKVAH, Israel , May 9, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , president and CEO, will present data from the company's Phase
View HTML
Toggle Summary Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14
Conference Call and Live Webcast at 8:30am Eastern Time NEW YORK and PETACH TIKVAH, Israel , May 8, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call to discuss its
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference
NEW YORK and PETACH TIKVAH, Israel , May 1, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that Ralph Kern , M.D., MHSc, Chief Operating Officer and Chief Medical Officer, will
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
NEW YORK and PETACH TIKVAH, Israel , April 11, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will present at the Alliance for
View HTML
Toggle Summary Letter To Shareholders
Toggle Summary BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients
Canada-Based ALS Patients Can Be Enrolled at The University of Massachusetts NEW YORK and PETACH TIKVAH, Israel , March 28, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announces that
View HTML
Toggle Summary BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 21, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced the appointments of Stanley H.
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum
HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 15, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chief Executive Officer, and Dr.
View HTML
Toggle Summary BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 12, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the formation of its Scientific Advisory Board (SAB) and the appointment
View HTML
Toggle Summary BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
Conference Call and Webcast @ 8:30 a.m. Eastern Time Today NEW YORK and PETACH TIKVAH, Israel , March 8, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for
View HTML
Toggle Summary BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8
HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 5, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call on Thursday, March 8 to discuss financial results for the
View HTML
Toggle Summary BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 7, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing ALSFRS-R subgroup analyses and
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 6, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits , President & Chief Executive Officer, will provide a
View HTML
Toggle Summary BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 5, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the appointment of Anthony (Tony) Polverino , Ph.D., to its board of
View HTML
Toggle Summary BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22
HACKENSACK, N.J. and PETACH TIKVA, Israel , Jan. 16, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits , President & CEO, and Dr.
View HTML
Toggle Summary BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn®
HACKENSACK, N.J. and PETACH TIKVA, Israel , Jan. 3, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has received Good Manufacturing Practice (GMP) approval from the Israel
View HTML
Tools
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds